Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
Maravai LifeSciences has acquired intellectual property and key assets from Molecular Assemblies, incorporating their proprietary enzymatic DNA synthesis platform into TriLink BioTechnologies. This strategic move aims to advance mRNA and CRISPR nucleic acid-based therapeutic development by improving oligonucleotide le…
Share This Article
Ready-to-post copy includes the article link.
Maravai LifeSciences Expands mRNA and Oligonucleotide Capabilities with Acquisition of Molecular Assemblies’ IP and Assets Maravai LifeSciences has acquired intellectual property and key assets from Molecular Assemblies, incorporating their proprietary enzymatic DNA synthesis platform into TriLink BioTechnologies. This strategic move aims t... Read the full IIPLA article: https://iipla.org/news/maravai-lifesciences-expands-mrna-and-oligonucleotide-capabilities-with-acquisition-of-molecular-assemblies-ip-and-assets